Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014
Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014
复制标题
DOI：
10.2807/1560-7917.es2014.19.30.20862
复制
发表时间：
2014-07-31
期刊：
影响因子：
19
通讯作者：
Unemo, M.
中科院分区：
文献类型：
--
作者：
Golparian, D.;Ohlsson, A. K.;Unemo, M.
我们描述了4例在瑞典证实治疗失败的咽部淋病与头孢曲松（500毫克; n=3）或头孢噻肟（500毫克; n=1）单药治疗。所有头孢曲松治疗失败是由国际传播的多重耐药淋球菌NG-MAST基因组1407克隆引起的。提高对治疗失败的认识是至关重要的，特别是当使用抗菌药物单药治疗时。频繁的治愈测试和适当的验证/伪造可疑的治疗失败，以及建议的双重抗菌治疗的实施是必要的。
We describe four cases in Sweden of verified treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg; n=3) or cefotaxime (500 mg; n=1) monotherapy. All the ceftriaxone treatment failures were caused by the internationally spreading multidrug-resistant gonococcal NG-MAST genogroup 1407 clone. Increased awareness of treatment failures is crucial particularly when antimicrobial monotherapy is used. Frequent test of cure and appropriate verification/falsification of suspected treatment failures, as well as implementation of recommended dual antimicrobial therapy are imperative.